Intercytex turns to Vavelta and cuts staff
27 March 2009
Sita Shah
sita.shah@informa.com
Intercytex will focus on developing Vavelta after the disappointing Phase III results of its lead wound care candidate Cyzact (ICX-PRO). It is cutting 26 jobs, shrinking its workforce from 76 to 50, as part of a restructuring programme announced in January to eventually reduce the headcount by half...
Please Login to read the full article.